Management of myelodysplastic syndromes relapsing after allogeneic hematopoietic stem-cell transplantation: a study by the SFGM-TC.
Fiche publication
Date publication
août 2015
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LIOURE Bruno
Tous les auteurs :
Guieze R, Damaj G, Pereira B, Robin M, Chevallier P, Michallet M, Vigouroux S, Beguin Y, Blaise D, Roos-Weil D, Thiebaut A, Rohrlich PS, Huynh A, Cornillon J, Contentin N, Suarez F, Lioure B, Mohty M, Maillard N, Clement L, Francois S, Guillerm G, Yakoub-Agha I
Lien Pubmed
Résumé
To find out prognostic factors and to investigate different therapeutic approaches, we report on 147 consecutive patients who relapsed after allogeneic hematopoietic stem cell transplantation (allo-SCT) for myelodysplastic syndrome (MDS). Sixty-two patients underwent immunotherapy (second allo-SCT or donor lymphocyte infusion; IT Group), 39 received cytoreductive treatment alone (CRT Group), and 46 were managed with palliative/supportive cares (PSC Group). Two-year OS was 32%, 6%, and 2% in the IT, CRT, and PSC Groups, respectively (P < .001). In multivariate analysis, 4 factors adversely influenced 2-year OS: history of acute graft-versus-host disease (HR=1.83; 95% CI=1.26-2.67; P=.002), relapse within 6 months (HR=2.69; 95% CI=0.82-3.98; P
Référence
Biol Blood Marrow Transplant. 2015 Aug 6. pii: S1083-8791(15)00517-0